Company news

Aytu BioPharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results

May 10, 2023

Aytu BioPharma Subleases a Portion of Its Manufacturing Facility

April 30, 2023

Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer

April 26, 2023

Aytu BioPharma Reports Second Quarter of Fiscal Year 2023

February 20, 2023

Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results

February 13, 2023

Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023

February 6, 2023

Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance

January 24, 2023

Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients

January 9, 2023

Aytu BioPharma Announces 1-for-20 Reverse Stock Split

January 4, 2023

Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect

November 29, 2022

Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso

November 15, 2022

Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023

November 13, 2022

Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022

November 6, 2022

Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan

October 24, 2022

Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs

October 12, 2022

Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions

October 4, 2022

Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue

September 26, 2022

Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin

September 13, 2022

Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin

August 15, 2022

Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering

August 14, 2022

Aytu BioPharma Announces Pricing of Public Offering

August 8, 2022

Aytu BioPharma Announces Launch of Public Offering

August 7, 2022

Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome

July 19, 2022

Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

June 28, 2022

Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities

May 15, 2022

Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology

April 24, 2022

Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome

April 18, 2022

Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)

March 22, 2022

Aytu BioPharma Announces Closing of $7.6 Million Registered Offering

March 6, 2022

Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering

March 1, 2022

Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome

March 1, 2022

Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results

February 13, 2022

Aytu BioPharma Completes $15 Million Debt Refinancing

January 30, 2022

Aytu BioPharma Appoints Mark Oki as Chief Financial Officer

January 3, 2022

Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome

December 12, 2021

Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome

December 7, 2021

Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter

November 22, 2021

Aytu BioPharma Reports First Quarter 2022 Financial Results

November 14, 2021

Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results

September 26, 2021

Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome

September 8, 2021

Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus

July 26, 2021

Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study

June 27, 2021

Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells

May 11, 2021

Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021

May 9, 2021

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

April 11, 2021

Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer

April 4, 2021

Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma

March 31, 2021

Aytu BioScience Announces Close of Merger with Neos Therapeutics

March 21, 2021

Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients

March 7, 2021

Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year

February 10, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.